최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기Scientific reports, v.6, 2016년, pp.32258 -
Bae, Song Yi (College of Pharmacy, Natural Products Research Institute, Seoul National University , Seoul 151-742, Korea) , Park, Hyen Joo (College of Pharmacy, Natural Products Research Institute, Seoul National University , Seoul 151-742, Korea) , Hong, Ji-Young (College of Pharmacy, Natural Products Research Institute, Seoul National University , Seoul 151-742, Korea) , Lee, Hye-Jung (College of Pharmacy, Natural Products Research Institute, Seoul National University , Seoul 151-742, Korea) , Lee, Sang Kook (College of Pharmacy, Natural Products Research Institute, Seoul National University , Seoul 151-742, Korea)
The failure of targeted therapy due to the resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib, is considered a major problem in the treatment of non-small cell lung cancer (NSCLC) patients. SerpinB2, a component of the urokinase plasminogen activ...
Zhu C. Q. & Tsao M. S. Prognostic markers in lung cancer: is it ready for prime time? Transl Lung Cancer Res 3 , 149 – 158 ( 2014 ). 25806294
Byers L. A. . An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance . Clin Cancer Res 19 , 279 – 290 ( 2013 ). 23091115
Seo J. S. . The transcriptional landscape and mutational profile of lung adenocarcinoma . Genome Res 22 , 2109 – 2119 ( 2012 ). 22975805
Yoshino H. , Endo Y. , Watanabe Y. & Sasaki T. Significance of plasminogen activator inhibitor 2 as a prognostic marker in primary lung cancer: association of decreased plasminogen activator inhibitor 2 with lymph node metastasis . Br J Cancer 78 , 833 – 839 ( 1998 ). 9743310
He C. , He P. , Liu L. P. & Zhu Y. S. Analysis of expressions of components in the plasminogen activator system in high- and low-metastatic human lung cancer cells . J Cancer Res Clin Oncol 127 , 180 – 186 ( 2001 ). 11260863
Robert C. . Expression of plasminogen activator inhibitors 1 and 2 in lung cancer and their role in tumor progression . Clin Cancer Res 5 , 2094 – 2102 ( 1999 ). 10473092
Kruithof E. K. , Baker M. S. & Bunn C. L. Biological and clinical aspects of plasminogen activator inhibitor type 2 . Blood 86 , 4007 – 4024 ( 1995 ). 7492756
Blasi F. & Carmeliet P. uPAR: a versatile signalling orchestrator . Nat Rev Mol Cell Biol 3 , 932 – 943 ( 2002 ). 12461559
Ranson M. & Andronicos N. M. Plasminogen binding and cancer: promises and pitfalls . Front Biosci 8 , s294 – s304 ( 2003 ). 12700073
Al-Ejeh F. , Croucher D. & Ranson M. Kinetic analysis of plasminogen activator inhibitor type-2: urokinase complex formation and subsequent internalisation by carcinoma cell lines . Exp Cell Res 297 , 259 – 271 ( 2004 ). 15194441
Croucher D. , Saunders D. N. & Ranson M. The urokinase/PAI-2 complex: a new high affinity ligand for the endocytosis receptor low density lipoprotein receptor-related protein . J Biol Chem 281 , 10206 – 10213 ( 2006 ). 16459332
Stefansson S. , McMahon G. A. , Petitclerc E. & Lawrence D. A. Plasminogen activator inhibitor-1 in tumor growth, angiogenesis and vascular remodeling . Curr Pharm Des 9 , 1545 – 1564 ( 2003 ). 12871067
Webb D. J. , Thomas K. S. & Gonias S. L. Plasminogen activator inhibitor 1 functions as a urokinase response modifier at the level of cell signaling and thereby promotes MCF-7 cell growth . J Cell Biol 152 , 741 – 752 ( 2001 ). 11266465
Croucher D. R. , Saunders D. N. , Lobov S. & Ranson M. Revisiting the biological roles of PAI2 (SERPINB2) in cancer . Nat Rev Cancer 8 , 535 – 545 ( 2008 ). 18548086
Duffy M. J. The urokinase plasminogen activator system: role in malignancy . Curr Pharm Des 10 , 39 – 49 ( 2004 ). 14754404
Ulisse S. , Baldini E. , Sorrenti S. & D’Armiento M. The urokinase plasminogen activator system: a target for anti-cancer therapy . Curr Cancer Drug Targets 9 , 32 – 71 ( 2009 ). 19200050
Duffy M. J. & Duggan C. The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer . Clin Biochem 37 , 541 – 548 ( 2004 ). 15234235
Foekens J. A. . The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients . Cancer Res 60 , 636 – 643 ( 2000 ). 10676647
Shiomi H. , Eguchi Y. , Tani T. , Kodama M. & Hattori T. Cellular distribution and clinical value of urokinase-type plasminogen activator, its receptor, and plasminogen activator inhibitor-2 in esophageal squamous cell carcinoma . Am J Pathol 156 , 567 – 575 ( 2000 ). 10666386
Nakamura M. . Possible role of plasminogen activator inhibitor 2 in the prevention of the metastasis of gastric cancer tissues . Thromb Res 65 , 709 – 719 ( 1992 ). 1636163
Zhou L. . Low expression of PAI-2 as a novel marker of portal vein tumor thrombosis and poor prognosis in hepatocellular carcinoma . World J Surg 37 , 608 – 613 ( 2013 ). 23188538
Huang Z. . SERPINB2 down-regulation contributes to chemoresistance in head and neck cancer . Mol Carcinog 53 , 777 – 786 ( 2014 ). 23661500
Yilmaz M. & Christofori G. EMT, the cytoskeleton, and cancer cell invasion . Cancer Metastasis Rev 28 , 15 – 33 ( 2009 ). 19169796
Yamaguchi H. & Condeelis J. Regulation of the actin cytoskeleton in cancer cell migration and invasion . Biochim Biophys Acta 1773 , 642 – 652 ( 2007 ). 16926057
Schroder W. A. . Tumor cell-expressed SerpinB2 is present on microparticles and inhibits metastasis . Cancer Med 3 , 500 – 513 ( 2014 ). 24644264
Wang S. . Study on invadopodia formation for lung carcinoma invasion with a microfluidic 3D culture device . PLoS One 8 , e56448 ( 2013 ). 23441195
Hong J. Y. , Chung H. J. , Lee H. J. , Park H. J. & Lee S. K. Growth inhibition of human lung cancer cells via down-regulation of epidermal growth factor receptor signaling by yuanhuadine, a daphnane diterpene from Daphne genkwa . J Nat Prod 74 , 2102 – 2108 ( 2011 ). 21916433
Bae S. Y. , Hong J. Y. , Lee H. J. , Park H. J. & Lee S. K. Targeting the degradation of AXL receptor tyrosine kinase to overcome resistance in gefitinib-resistant non-small cell lung cancer . Oncotarget 6 , 10146 – 10160 ( 2015 ). 25760142
Stylli S. S. , Kaye A. H. & Lock P. Invadopodia: at the cutting edge of tumour invasion . J Clin Neurosci 15 , 725 – 737 ( 2008 ). 18468901
Courtneidge S. A. Cell migration and invasion in human disease: the Tks adaptor proteins . Biochem Soc Trans 40 , 129 – 132 ( 2012 ). 22260678
Hong J. Y. , Nam J. W. , Seo E. K. & Lee S. K. Daphnane diterpene esters with anti-proliferative activities against human lung cancer cells from Daphne genkwa . Chem Pharm Bull (Tokyo) 58 , 234 – 237 ( 2010 ). 20118586
Thiery J. P. , Acloque H. , Huang R. Y. & Nieto M. A. Epithelial-mesenchymal transitions in development and disease . Cell 139 , 871 – 890 ( 2009 ). 19945376
Tsai C. M. , Yen G. C. , Sun F. M. , Yang S. F. & Weng C. J. Assessment of the anti-invasion potential and mechanism of select cinnamic acid derivatives on human lung adenocarcinoma cells . Mol Pharm 10 , 1890 – 1900 ( 2013 ). 23560439
Mekkawy A. H. , Pourgholami M. H. & Morris D. L. Involvement of urokinase-type plasminogen activator system in cancer: an overview . Med Res Rev 34 , 918 – 956 ( 2014 ). 24549574
Darnell G. A. . Inhibition of retinoblastoma protein degradation by interaction with the serpin plasminogen activator inhibitor 2 via a novel consensus motif . Mol Cell Biol 23 , 6520 – 6532 ( 2003 ). 12944478
Li J. , Li Y. , Feng Z. Q. & Chen X. G. Anti-tumor activity of a novel EGFR tyrosine kinase inhibitor against human NSCLC in vitro and in vivo . Cancer Lett 279 , 213 – 220 ( 2009 ). 19299077
Bouchet C. . Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas . Br J Cancer 69 , 398 – 405 ( 1994 ). 8297742
Nozaki S. . Immunohistochemical localization of a urokinase-type plasminogen activator system in squamous cell carcinoma of the oral cavity: association with mode of invasion and lymph node metastasis . Oral Oncol 34 , 58 – 62 ( 1998 ). 9659521
Andreasen P. A. , Kjoller L. , Christensen L. & Duffy M. J. The urokinase-type plasminogen activator system in cancer metastasis: a review . Int J Cancer 72 , 1 – 22 ( 1997 ). 9212216
Linder S. The matrix corroded: podosomes and invadopodia in extracellular matrix degradation . Trends Cell Biol 17 , 107 – 117 ( 2007 ). 17275303
Cargnello M. & Roux P. P. Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases . Microbiol Mol Biol Rev 75 , 50 – 83 ( 2011 ). 21372320
Croucher D. R. , Saunders D. N. , Stillfried G. E. & Ranson M. A structural basis for differential cell signalling by PAI-1 and PAI-2 in breast cancer cells . Biochem J 408 , 203 – 210 ( 2007 ). 17696882
Lee S. . Profiling of transcripts and proteins modulated by K-ras oncogene in the lung tissues of K-ras transgenic mice by omics approaches . Int J Oncol 34 , 161 – 172 ( 2009 ). 19082487
Kostenko S. , Dumitriu G. & Moens U. Tumour promoting and suppressing roles of the atypical MAP kinase signalling pathway ERK3/4-MK5 . J Mol Signal 7 , 9 ( 2012 ). 22800433
Lee M. S. . Snail1 induced in breast cancer cells in 3D collagen I gel environment suppresses cortactin and impairs effective invadopodia formation . Biochim Biophys Acta 1843 , 2037 – 2054 ( 2014 ). 24861866
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
오픈액세스 학술지에 출판된 논문
※ AI-Helper는 부적절한 답변을 할 수 있습니다.